Merck Provides Update on Phase III Clinical Program for Preladenant, the Company’s Investigational Parkinson’s Disease Medicine

New Drug Approvals

preladenant

Merck , known as MSD outside the United States and Canada, today provided an update on the clinical program for preladenant, Merck’s investigational adenosine A2A receptor antagonist for the treatment of Parkinson’s disease (PD). An initial review of data from three separate Phase III trials did not provide evidence of efficacy for preladenant compared with placebo…..read more at

Links

http://www.businesswire.com/news/home/20130523006358/en/Merck-Update-Phase-III-Clinical-Program-Preladenant

Preladenant (SCH 420814) was a drug that was developed by Schering-Plough which acted as a potent and selective antagonist at the adenosine A2A receptor. It was being researched as a potential treatment for Parkinson’s disease.Positive results were reported in Phase II clinical trials in humans, but it did not prove itself to be more effective than a placebo during Phase III trials, and so was discontinued in May 2013

View original post

Sanofi and Regeneron’s dupilumab for asthma. The partners have unveiled Phase IIa data at the American Thoracic Society meeting in Philadelphia on dupilumab, an interleukin 4 receptor which modulates signalling of both the IL-4 and IL-13 proteins, which are linked to inflammation

New Drug Approvals

Dupilumab is a monoclonal antibody designed for the treatment of atopic diseases.It binds to the alpha subunit of the interleukin-4 receptor. Through blockade of IL-4R alpha, dupilumab modulates signaling of both the IL-4 and IL-13 pathway, which have been implicated in the pathophysiology of allergic disease.

This drug was developed by Regeneron Pharmaceuticals.

On May 21/2013 mid-stage data was presented at the American Thoracic Society meeting and published in the NEJM demonstrating a 87% reduction in asthma exacerbations in patients with moderate-to-severe allergic asthma.

The long-standing alliance between Sanofi and Regeneron looks to have scored another clinical goal, this time with dupilumab for asthma.

The partners have unveiled Phase IIa data at the American Thoracic Society meeting in Philadelphia on dupilumab, an interleukin 4 receptor which modulates signalling of both the IL-4 and IL-13 proteins, which are linked to inflammation. The 104-patient study enrolled 104 patients with moderate-to-severe, persistent…

View original post 24 more words

Fish Oil Pills Might Cut Diabetes Risk, Researchers Say (Drugs.com)

New Drug Approvals

fishoil-1WEB

Fish oil supplements could help reduce the risk for type 2 diabetes, new research suggests.

The supplements, also known as omega-3 fatty acids, increase levels of a hormone called adiponectin that’s linked to insulin sensitivity, Harvard researchers found. Higher levels of this hormone in the bloodstream have also been linked to a lower risk for heart disease.

read all at Drugs.com

http://www.drugs.com/news/fish-oil-pills-might-cut-diabetes-risk-researchers-say-44671.html

View original post

Bitter Melon (Momordica charantia Linn.)(fruit) Dried water extract).help steady your blood sugar levels

New Drug Approvals

Helps support normal blood sugar levels with compounds called charantin and momordicin. Additional key compounds such as vicine, peptides, and polypeptide-p (plant insulin) also work together to give Bitter Melon its potency.

Bitter Melon (Momordica charantia Linn.)(fruit) Dried water extract).

The balance between the good things and bad things you eat is sometimes hard to keep steady. Bitter Melon is a natural fruit that can help steady your blood sugar levels, as it works to promote normal blood sugar levels in your body. Thus it is a reliable safety net when you need glycemic control.

Bitter Melon is different than many other herbs in that it is often eaten as a dish. Thus it is proven safe to ingest. Bitter Melon is an unique fruit with good nutritional value, which is why Health Canada recommends it on their website as a way to “Treat Your Taste Buds” (Health Canada, Feb…

View original post 139 more words

ARAB MEDICINE- KHAT

New Drug Approvals

Catha edulis

Khat (Catha edulis) is a flowering plant native to the Horn of Africa and the Arabian Peninsula. Among communities from these areas, khat chewing has a long history as a social custom dating back thousands of years.

Khat contains a monoamine alkaloid called cathinone, an amphetamine-like stimulant, which is said to cause excitement, loss of appetite and euphoria. In 1980, the World Health Organization (WHO) classified it as a drug of abuse that can produce mild to moderatepsychological dependence (less than tobacco or alcohol), although the WHO does not consider khat to be seriously addictive. The plant has been targeted by anti-drug organizations such as the DEA.It is a controlled substance in some countries, such as the United States, Canada and Germany, while its production, sale and consumption are legal in other nations, including Djibouti, Ethiopia, Somalia and Yemen.

 

Man chewing khat in Sana’a, Yemen, January 2009

Khat is a slow-growing shrub or tree that grows to between 1.4 m and 3.1 m tall, depending on region and rainfall. It has evergreenleaves 5–10 cm long and 1–4 cm broad. The flowers are produced on short axillary cymes 4–8 cm long. Each flower is small, with…

View original post 598 more words